AbbVie (MEX:ABBV) FFO


MEX:ABBV AbbVie Inc MEX:ABBV
72 GF Score
Price MXN4,245.00
GF Value MXN3,691.02
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie FFO?

FFO (Funds from operations) only applies to REITs.

MEX:ABBV
72GF Score
AbbVie Inc MEX:ABBV
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,245.00 is trading 15% above its estimated GF Value™ of MXN3,691.02. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • FFO:
  • GF Value™: MXN3,691.02 vs. price of MXN4,245.00 (15% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
72GF Score

Get the complete analysis for MEX:ABBV

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,245.00
Price
MXN3,691.02
GF Value